Example: Heart Attack

Clinical Trials on Stage IV Solid Tumors

Total 66 results

  • NCT05837767
    Recruiting
    A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
    Melanoma Sarcoma Renal Cell Carcinoma Pancreatic Cancer NSCLC Non Small Cell Lung Cancer Bladder Cancer Metastatic Solid Tumor Gastrointestinal Cancer Lobular Breast Carcinoma
  • NCT05703243
    Recruiting
    Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II") (DINOSAur II)
    Stage III Solid Tumors Stage IV Solid Tumors
  • NCT05692466
    Recruiting
    Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur") (DINOSAur)
    Stage III Solid Tumors Stage IV Solid Tumors
  • NCT05269381
    Recruiting
    Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
    Metastatic Renal Cell Carcinoma Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma
  • NCT05039801
    Recruiting
    IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
    Chondrosarcoma Advanced Malignant Solid Neoplasm Stage III Uterine Corpus Cancer AJCC v8 Stage IV Uterine Corpus Cancer AJCC v8 Stage IVA Uterine Corpus Cancer AJCC v8 Stage IVB Uterine Corpus Cancer AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • NCT04940299
    Recruiting
    Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
    Malignant Solid Neoplasm Metastatic Lung Non-Small Cell Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Metastatic Melanoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Unresectable Melanoma Clinical Stage III Cutaneous Melanoma AJCC v8
  • NCT04902040
    Recruiting
    Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
    Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Advanced Malignant Solid Neoplasm Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8
  • NCT04771520
    Recruiting
    Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
    Prognostic Stage IIIC Breast Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Metastatic Melanoma Stage IV Lung Cancer AJCC v8 Locally Advanced Malignant Solid Neoplasm Locally Advanced Melanoma Metastatic Malignant Solid Neoplasm
  • NCT04514497
    Recruiting
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
    Stage III Pancreatic Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Metastatic Pancreatic Adenocarcinoma Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Unresectable Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Pancreatic Adenocarcinoma Metastatic Lung Small Cell Carcinoma Metastatic Neuroendocrine Carcinoma
  • NCT04514484
    Recruiting
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
    HIV Infection Metastatic Renal Cell Carcinoma Anatomic Stage III Breast Cancer AJCC v8 Recurrent Ovarian Carcinoma Metastatic Lung Non-Small Cell Carcinoma Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Melanoma Recurrent Head and Neck Carcinoma Recurrent Renal Cell Carcinoma Advanced Malignant Solid Neoplasm
  • NCT04314401
    Recruiting
    National Cancer Institute "Cancer Moonshot Biobank"
    Malignant Solid Neoplasm Acute Myeloid Leukemia Plasma Cell Myeloma Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Stage IVB Prostate Cancer AJCC v8
  • NCT04007744
    Recruiting
    Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
    Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Metastatic Melanoma Stage IV Lung Cancer AJCC v8 Unresectable Malignant Solid Neoplasm Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Malignant Solid Neoplasm Unresectable Melanoma
  • NCT03819296
    Recruiting
    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
    Malignant Solid Neoplasm Colitis Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8
  • NCT03213678
    Recruiting
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    Malignant Glioma Rhabdoid Tumor Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Solid Neoplasm
  • NCT03155620
    Recruiting
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    Malignant Glioma Rhabdoid Tumor Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Solid Neoplasm
  • NCT02419495
    Recruiting
    Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
    Metastatic Renal Cell Carcinoma Metastatic Lung Non-Small Cell Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Metastatic Melanoma Fallopian Tube Carcinoma Advanced Malignant Solid Neoplasm Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage III Renal Cell Cancer AJCC v8
  • NCT01738139
    Recruiting
    Ipilimumab and Imatinib Mesylate in Advanced Cancer
    Metastatic Melanoma Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Melanoma C-KIT Tyrosine Kinase Protein Overexpression Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Gastrointestinal Stromal Tumor Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Solid Neoplasm
  • NCT01365169
    Recruiting
    Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
    Pancreatic Adenocarcinoma Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Malignant Neoplasm Recurrent Colorectal Carcinoma Pancreatic Neuroendocrine Carcinoma Malignant Head and Neck Neoplasm Stage III Nasopharyngeal Carcinoma AJCC v7 Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • NCT02721732
    Active, not recruiting
    Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
    Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Metastatic Skin Squamous Cell Carcinoma Unresectable Solid Neoplasm Metastatic Kidney Medullary Carcinoma Metastatic Penile Carcinoma Small Cell Carcinoma Metastatic Adrenal Gland Pheochromocytoma Stage IV Penile Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7
  • NCT03233204
    Active, not recruiting
    Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    Malignant Glioma Recurrent Childhood Ependymoma Rhabdoid Tumor Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma
  • NCT03213665
    Active, not recruiting
    Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma Rhabdoid Tumor Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Ann Arbor Stage III Hodgkin Lymphoma Ann Arbor Stage IV Hodgkin Lymphoma Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma
  • NCT01989585
    Active, not recruiting
    Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
    Malignant Solid Neoplasm Metastatic Melanoma Unresectable Melanoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8
  • NCT02020707
    Active, not recruiting
    Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
    Malignant Solid Neoplasm Ovarian Endometrioid Adenocarcinoma Ovarian Undifferentiated Carcinoma Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Malignant Peritoneal Neoplasm Endometrial Clear Cell Adenocarcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma
  • NCT02304458
    Completed
    Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
    Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Refractory Malignant Solid Neoplasm Recurrent Melanoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma
  • NCT02298959
    Active, not recruiting
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
    Sarcoma Metastatic Renal Cell Carcinoma Metastatic Melanoma Recurrent Renal Cell Carcinoma Recurrent Melanoma Stage IV Renal Cell Cancer AJCC v8 Metastatic Malignant Solid Neoplasm Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8
  • NCT02595866
    Active, not recruiting
    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
    HIV Infection Hepatocellular Carcinoma Non-Hodgkin Lymphoma Metastatic Lung Non-Small Cell Carcinoma Metastatic Melanoma Kaposi Sarcoma Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm
  • NCT02496208
    Active, not recruiting
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
    Malignant Solid Neoplasm Metastatic Renal Cell Carcinoma Metastatic Clear Cell Renal Cell Carcinoma Advanced Clear Cell Renal Cell Carcinoma Metastatic Malignant Neoplasm in the Bone Metastatic Bladder Urothelial Carcinoma Metastatic Renal Pelvis Urothelial Carcinoma Metastatic Ureter Urothelial Carcinoma Metastatic Urethral Urothelial Carcinoma Metastatic Bladder Small Cell Neuroendocrine Carcinoma
  • NCT01303341
    Active, not recruiting
    Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
    Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Recurrent Melanoma Stage IIIC Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7
  • NCT01364051
    Active, not recruiting
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
    Metastatic Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Refractory Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm
  • NCT03213691
    Active, not recruiting
    Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
    Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Primary Central Nervous System Neoplasm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma Recurrent Childhood Central Nervous System Neoplasm
  • NCT03220035
    Active, not recruiting
    Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    Soft Tissue Sarcoma Osteosarcoma Ewing Sarcoma Malignant Glioma Ependymoma Rhabdoid Tumor Advanced Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Rhabdomyosarcoma Recurrent Malignant Solid Neoplasm
  • NCT01480154
    Active, not recruiting
    Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
    Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Advanced Malignant Solid Neoplasm Stage IIIC Cutaneous Melanoma AJCC v7 Stage III Renal Cell Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IV Prostate Cancer AJCC v7 Stage III Prostate Cancer AJCC v7
  • NCT01638533
    Active, not recruiting
    Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
    Glioma Hematopoietic and Lymphoid Cell Neoplasm Lymphoma Recurrent Head and Neck Carcinoma Recurrent Lung Carcinoma Recurrent Renal Cell Carcinoma Stage III Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7
  • NCT02013492
    Completed
    Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
    Hepatocellular Carcinoma Unspecified Adult Solid Tumor, Protocol Specific Recurrent Melanoma Male Breast Cancer Stage IV Breast Cancer Stage IV Melanoma Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor
  • NCT01902173
    Active, not recruiting
    Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
    Hematopoietic and Lymphoid Cell Neoplasm Metastatic Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Locally Advanced Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm Locally Advanced Melanoma Metastatic Malignant Solid Neoplasm Stage IIIC Cutaneous Melanoma AJCC v7 Unresectable Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations